Antinociceptive activity of the tachykinin NK1 receptor antagonist, CP‐99,994, in conscious gerbils

1 The ability of CP‐99,994, and its less active enantiomer, CP‐100,263, to inhibit spontaneous behaviours and hyperalgesia induced by central infusion of the NK1 receptor agonist, GR73632 or intraplantar injection of formalin was investigated in rats and gerbils 2 GR73632 (3 pmol, i.c.v.)‐induced foot tapping in gerbils was dose‐dependently inhibited by CP‐99,994 (0.1‐1 mg kg−1, s.c), but not by CP‐100,263 (10 mg kg−1, s.c.) using pretreatment times up to 60 min. The centrally active dose‐range for CP‐99,994 was increased to 1 −10 mg kg−1 s.c. with a higher challenge dose of GR73632 (30 pmol, i.e.v.) 3 In gerbils, intrathecal (i.t.) injection of GR73632 (30 pmol) elicited behaviours (licking, foot tapping or flinching and face washing) which closely resembled, but which was less specifically localized than, behaviours seen in animals injected with formalin (0.1–5%) into one hindpaw 4 In rats, CP‐100,263, but not CP‐99,994 (up to 30 mg kg−1), inhibited the early phase response to intraplantar injection of 5% formalin (ID50= 13.9 mg kg−1. The late phase was inhibited by both compounds (ID50 values 36.3 and 20.9 mg kg−1, respectively). In gerbils, there was marginal evidence for enantioselective inhibition of the early phase induced by formalin (2%). The ID50 values were 6.2 mg kg−1 for CP‐99,994 and 13.4 mg kg−1 for CP‐100,263 5 Intrathecal injection of GR73632 (30 pmol) caused thermal hyperalgesia in gerbils which was inhibited enantioselectively by s.c. administration of CP‐99,994 (ID50 = 2.46 mg kg−1, but not by CP‐100,263 (30 mg kg−1) 6 In gerbils, intraplantar injection of formalin (0.1%) caused thermal hyperalgesia which was inhibited by CP‐99,994 (ID50= 1.1 mg kg−1, s.c). There was a nonsignificant trend for an anti‐algesic effect of CP‐100,236 (estimated ID50 = 8.2 mg kg−1, s.c) 7 These findings support the proposal that NKi receptor antagonists may be useful in the clinical management of pain and reinforce the need to dissociate specific and nonspecific antinociceptive effects of available compounds.

[1]  K. Tan-No,et al.  The neurokinin-1 receptor antagonist, sendide, exhibits antinociceptive activity in the formalin test , 1995, Pain.

[2]  S. Harrison,et al.  Non-specific effects of the tachykinin NK1 receptor antagonist, CP-99,994, in antinociceptive tests in rat, mouse and gerbil. , 1994, European journal of pharmacology.

[3]  N. Rupniak,et al.  Differential inhibition of foot tapping and chromodacryorrhoea in gerbils by CNS penetrant and non-penetrant tachykinin NK1 receptor antagonists. , 1994, European journal of pharmacology.

[4]  N. Rupniak,et al.  Non-specific inhibition of dopamine receptor agonist-induced behaviour by the tachykinin NK1 receptor antagonist CP-99,994 in guinea-pigs. , 1994, European journal of pharmacology.

[5]  J. Marchand,et al.  Altered tachykinin expression by dorsal root ganglion neurons in a rat model of neuropathic pain , 1994, Pain.

[6]  O. Berge,et al.  (±)-CP-96,345, an NK1 receptor antagonist, has local anaesthetic-like effects in a mammalian sciatic nerve preparation , 1994, Regulatory Peptides.

[7]  S. Freedman,et al.  Characterisation of CCKB receptors on GH3 pituitary cells: receptor activation is linked to Ca2+ mobilisation. , 1994, European journal of pharmacology.

[8]  M. Spedding,et al.  Differential effects of non-peptidic tachykinin receptor antagonists on Ca2+ channels. , 1994, European journal of pharmacology.

[9]  R. Hill.  Role of Receptors in Nociception , 1994 .

[10]  S. Iversen,et al.  Antinociceptive activity of NK1 receptor antagonists: non‐specific effects of racemic RP67580 , 1993, British journal of pharmacology.

[11]  A. Ganong,et al.  Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor. , 1993, The Journal of pharmacology and experimental therapeutics.

[12]  A. Dickenson,et al.  The effect of intrathecal administration of RP67580, a potent neurokinin 1 antagonist on nociceptive transmission in the rat spinal cord , 1993, Neuroscience Letters.

[13]  R. Hargreaves,et al.  Effect of RP 67580, a non‐peptide neurokinin1 receptor antagonist, on facilitation of a nociceptive spinal flexion reflex in the rat , 1993, British journal of pharmacology.

[14]  T. Coderre,et al.  CP-96,345, but not its stereoisomer, CP-96,344, blocks the nociceptive responses to intrathecally administered substance P and to noxious thermal and chemical stimuli in the rat , 1993, Neuroscience.

[15]  T. Yaksh,et al.  Effects of intrathecal capsaicin and an NK-1 antagonist, CP,96-345, on the thermal hyperalgesia observed following unilateral constriction of the sciatic nerve in the rat , 1992, Pain.

[16]  A. Murase,et al.  Non-specific activity of (±) CP-96,345 in models of pain and inflammation , 1992, Regulatory Peptides.

[17]  Anne W. Schmidt,et al.  The substance P receptor antagonist CP-96,345 interacts with Ca2+ channels. , 1992, European journal of pharmacology.

[18]  A. Ganong,et al.  Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin NK1 receptor , 1992, Regulatory Peptides.

[19]  A. Malmberg,et al.  Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. , 1992, Science.

[20]  Z. Wiesenfeld‐Hallin,et al.  Intrathecal CP-96,345 blocks reflex facilitation induced in rats by substance P and C-fiber-conditioning stimulation. , 1992, European journal of pharmacology.

[21]  C. Garret,et al.  RP 67580, a non-peptide substance P antagonist, inhibits neurogenic inflammation and possesses antinociceptive activities in rodents , 1992, Neuropeptides.

[22]  C. Maggi,et al.  Characterization of the tachykinin NK-2 receptor in the human urinary bladder by means of selective antagonists , 1992, Neuropeptides.

[23]  S. Harrison,et al.  The non‐peptide NK1 receptor antagonist, (±)‐CP‐96,345, produces antinociceptive and anti‐oedema effects in the rat , 1992, British journal of pharmacology.

[24]  Y. de Koninck,et al.  Substance P-mediated slow excitatory postsynaptic potential elicited in dorsal horn neurons in vivo by noxious stimulation. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. Laduron,et al.  Pharmacological properties of a potent and selective nonpeptide substance P antagonist. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Henry,et al.  Novel substance P antagonist, CP-96,345, blocks responses of cat spinal dorsal horn neurons to noxious cutaneous stimulation and to substance P , 1991, Neuroscience Letters.

[27]  R. Hagan,et al.  Investigation into species variants in tachykinin NK1 receptors by use of the non‐peptide antagonist, CP‐96,345 , 1991, British journal of pharmacology.

[28]  J. Howbert,et al.  Species differences in affinities of non-peptide antagonists for substance P receptors. , 1991, European journal of pharmacology.

[29]  T. Yamamoto,et al.  Stereospecific effects of a nonpeptidic NK1 selective antagonist, CP-96,345: antinociception in the absence of motor dysfunction. , 1991, Life sciences.

[30]  K. McCarson,et al.  Time course of the alteration in dorsal horn substance p levels following formalin: blockade by naloxone , 1990, Pain.

[31]  R. Dubner,et al.  A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia , 1987, Pain.

[32]  M. Zimmermann,et al.  Ethical guidelines for investigations of experimental pain in conscious animals , 1983, Pain.

[33]  G. Wilcox,et al.  Intrathecal morphine in mice: a new technique. , 1980, European journal of pharmacology.